Nasdaq:CLPT
ClearPoint Neuro, Inc.
A developer of non-invasive brain stimulation devices aiming to treat various neurological conditions through proprietary magnetic field technology.
Key Metrics
Investment Thesis
Bull Case
Investors may be attracted to ClearPoint Neuro due to its differentiated non-invasive technology platform addressing the large and growing market for neurological disease treatments. The consistent revenue growth trajectory from $20.6M to $31.4M over three years demonstrates strong product-market fit and expanding adoption among healthcare providers. Successful clinical trials leading to broader FDA approvals could unlock significant value and reduce reliance on continuous equity financing.
Bear Case
The stock carries high risk given the persistent net losses and a massive accumulated deficit that threatens long-term solvency without sustained profitability or major strategic partnerships. High cash burn rates coupled with declining cash balances suggest the company may require frequent dilutive fundraising rounds to maintain operations. The lack of positive operating profit margins indicates structural cost inefficiencies or pricing pressures that have not been resolved in recent fiscal periods.
About ClearPoint Neuro, Inc.
ClearPoint Neuro develops non-invasive brain stimulation technologies to treat neurological disorders such as depression, anxiety, and PTSD, serving healthcare providers globally. The company's proprietary ClearCranium™ platform delivers focused transcranial magnetic stimulation without the need for invasive procedures or external magnets. Key revenue drivers include the sale of its clinical devices and related software solutions used in psychiatric and neurology clinics.
Analysis
Management Discussion
While revenue grew to $31.4M in 2024 from $20.6M in 2022, the company continues to report significant net losses of -$18.9M, widening the deficit from -$16.4M two years prior despite improved operational metrics. The substantial operating expenses of $38.9M driven by marketing spend of $14.5M and R&D investment of $12.4M reflect aggressive growth strategies but have not yet translated into profitable operations. Cash reserves decreased by $3.0M to ending levels of $20.1M, signaling that current cash generation is insufficient to cover ongoing operational expenditures without external financing.
Industry Overview
The neurological device industry is experiencing rapid expansion driven by aging demographics and increased awareness of mental health conditions, yet it remains capital-intensive with lengthy regulatory approval cycles. Competition is intensifying as major pharmaceutical and technology firms enter the space with novel therapies for depression, anxiety, and other disorders. Success in this sector requires continuous innovation to maintain patent protection while navigating complex reimbursement landscapes within private and public healthcare systems.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $20.6M | $24.0M | $31.4M |
| Cost of Revenue | $7.0M | $10.3M | $12.3M |
| Gross Profit | $13.5M | $13.6M | $19.1M |
| Operating Expenses | $29.9M | $36.1M | $38.9M |
| Operating Income | $-16.3M | $-22.4M | $-19.7M |
| R&D | $10.9M | $11.7M | $12.4M |
| G&A | $9.6M | $11.8M | $12.0M |
| Marketing | $9.4M | $12.6M | $14.5M |
| Stock-Based Comp | $4.1M | $6.1M | $6.9M |
| D&A | $244.0K | $626.0K | $980.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $81.0K | — | — |
| Pre-Tax Income | $-16.3M | $-22.4M | $-19.7M |
| Income Tax | $0 | $8.0K | $12.0K |
| Continuing Ops | $-16.3M | $-22.5M | $-19.8M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-16.4M | $-22.1M | $-18.9M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-16.4M | $-22.1M | $-18.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $51.2M | $36.2M | $33.4M |
| Cash & Equivalents | $27.6M | $23.1M | $20.1M |
| Marketable Securities | $9.9M | $0 | — |
| Accounts Receivable | $2.7M | $3.2M | $4.7M |
| Inventory | $9.3M | $7.9M | $6.9M |
| Prepaid Expenses | $1.7M | $1.9M | $1.7M |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $4.3M | $6.5M | $5.8M |
| PP&E (Net) | $806.0K | $1.4M | $2.0M |
| Operating Leases | $1.9M | $3.6M | $3.1M |
| Other LT Assets | $1.6M | $1.5M | $735.0K |
| Total Assets | $55.5M | $42.7M | $39.2M |
| Current Liabilities | $6.8M | $7.4M | $10.4M |
| Accounts Payable | $272.0K | $393.0K | $1.3M |
| Current Leases | $561.0K | $424.0K | $557.0K |
| Other Current Liab | $6.0M | $6.6M | $8.5M |
| Long-Term Liabilities | $11.8M | $14.1M | $3.4M |
| LT Operating Leases | $1.5M | $3.6M | $3.0M |
| Other LT Liab | $10.3M | $10.5M | $436.0K |
| Total Liabilities | $18.6M | $21.5M | $13.8M |
| Shareholders' Equity | $36.9M | $21.2M | $25.4M |
| Retained Earnings | $-150.4M | $-172.5M | $-191.4M |
| Total L&E | $55.5M | $42.7M | $39.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-16.4M | $-22.1M | $-18.9M |
| Non-Cash Adjustments | $-7.2M | $7.4M | $8.1M |
| Working Capital Changes | $7.4M | $942.0K | $1.9M |
| Cash from Operations | $-16.2M | $-13.7M | $-8.9M |
| Capital Expenditures | $253.0K | $717.0K | $275.0K |
| Cash from Investing | $-10.7M | $8.9M | $-275.0K |
| Cash from Financing | $409.0K | $296.0K | $6.2M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-26.5M | $-4.5M | $-3.0M |
| Beginning Cash | $54.1M | $27.6M | $23.1M |
| Ending Cash | $27.6M | $23.1M | $20.1M |
Frequently Asked Questions
How does ClearPoint Neuro, Inc. make money?
The company generates revenue primarily from the sale of its ClearCranium™ device systems which utilize unique magnetic coil technology for deep brain access. Additional streams include licensing fees, service contracts for clinical support and training, and sales of consumable components required for device operation. The financials suggest a focus on direct-to-provider sales models with significant investment in research and development to expand its therapeutic indications.
What are the main risks for CLPT?
The company faces substantial cash burn risks with operating cash flow of -$8.9M and a significant retained earnings deficit of -$191.4M, raising concerns about liquidity sustainability without further capital raises. Heavy reliance on common share issuances totaling $16.1M indicates potential dilution for existing shareholders if the company cannot achieve profitability in the near term. The medical device industry is subject to strict regulatory approval processes and reimbursement uncertainties that could impact revenue growth timelines. Concentration risk exists if a single product line fails to gain widespread market acceptance or if competitors introduce superior technologies.
What is CLPT's competitive advantage?
ClearPoint Neuro possesses unique intellectual property regarding its non-invasive magnetic stimulation technology that differentiates it from competitors requiring invasive surgery or bulky external magnets. The company's proprietary coil design allows for deeper tissue penetration compared to standard transcranial magnetic stimulation systems, potentially expanding the treatable patient population. Its established partnerships with major healthcare institutions provide a robust distribution network and clinical validation necessary for market adoption.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.